Acceptability and Palatability of Novel Orodispersible Minitablets of Enalapril in Children up to the Age of 6 with Heart Failure
Open Access
- 30 January 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 915
Abstract
Background: Angiotensin-converting enzyme inhibitors, such as enalapril, are foundational in treating pediatric heart failure. However, they are often administered off-label to young children using extemporaneous formulations. This study, conducted as part of the EU-funded Labeling of Enalapril from Neonates up to Adolescents (LENA) project, aimed to evaluate the acceptability and palatability of an age-appropriate enalapril orodispersible minitablet (ODMT). These factors are critical for ensuring adherence, efficacy, and safety in pediatric patients. Methods: An 8-week trial was conducted in children with heart failure caused by dilated cardiomyopathy or congenital heart disease. Enalapril ODMTs (0.25 mg or 1.0 mg) were dose-titrated and administered to 38 children aged 0–6 months and 22 children aged 6 months to 6 years. This study aimed to assess its acceptability and palatability, key factors contributing to adherence, and therefore, efficacy and safety. Results: Across all 169 assessments in 38 children aged 0–6 months and 22 aged 6 months to 6 years, complete or partial swallowability was observed, and the acceptability rate was 100%. There were no cases of choking, inhalation/coughing, or spitting out. A favorable or neutral rating was observed in 96% of palatability assessments based on observations of facial expressions. Acceptability and palatability were higher in subjects aged 6 months–6 years than 0–6 months, with no significant influence from repeated administration. Conclusions: Enalapril ODMTs are widely accepted and well-tolerated among young children, including neonates, with heart failure. These findings suggest that ODMTs are a suitable and effective method for administering pediatric medicinal products.Keywords
Funding Information
- European Union Seventh Framework Program (602295)
This publication has 33 references indexed in Scilit:
- Paediatric specific dosage forms: Patient and formulation considerationsInternational Journal of Pharmaceutics, 2022
- Important Considerations in Pediatric Heart FailureCurrent Cardiology Reports, 2020
- Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety studyContemporary Clinical Trials Communications, 2019
- Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy AdultsClinical Pharmacology in Drug Development, 2019
- Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot studyInternational Journal of Pharmaceutics, 2015
- Regulatory perspectives on acceptability testing of dosage forms in childrenInternational Journal of Pharmaceutics, 2014
- Favorable Acceptance of Mini-Tablets Compared with Syrup: A Randomized Controlled Trial in Infants and Preschool ChildrenThe Journal of Pediatrics, 2013
- What can we do to make antihypertensive medications taste better for children?International Journal of Pharmaceutics, 2013
- Paediatric clinical pharmacology—at the beginning of a new eraEuropean Journal of Clinical Pharmacology, 2007
- Off label and unlicensed drugs use in paediatric cardiologyEuropean Journal of Clinical Pharmacology, 2005